Unjoni Ewropea - Malti - EMA (European Medicines Agency)

correvio - vernakalant hydrochloride - fibrilazzjoni atrijali - terapija kardijaka - konverżjoni mgħaġġla tal-bidu reċenti fibrillazzjoni atrijali għal sinus rhythm fl-adulti:għall-non-kirurġija il-pazjenti: fibrillazzjoni atrijali .

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - aġenti antineoplastiċi - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi b.v. - vandetanib - neoplażmi tat-tirojde - aġenti antineoplastiċi u immunomodulanti - caprelsa huwa indikat għat-trattament ta 'kanċer tat-tirojde mediterrali (mtc) aggressiv u sintomatiku f'pazjenti b'mard ta' lokalizzazzjoni avvanzat jew metastatiku li ma jistax jitneħħa. caprelsa huwa indikat fl-adulti, it-tfal u l-adolexxenti li għandhom bejn 5-il sena u anzjani. għal pazjenti li għalihom rranġati mill-ġdid il-waqt il-trasfezzjoni(ret) mutazzjoni mhux magħrufa jew negattiv, jista'jkun aktar baxxi benefiċċju għandu jkun kkunsidrat qabel it-trattament individwali id-deċiżjoni tal -.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - disfunzjoni erettili - uroloġiċi - trattament ta 'disfunzjoni erettili. sabiex tadalafil ikun effettiv, l-istimulazzjoni sesswali hija meħtieġa. cialis mhuwiex indikat għall-użu min-nisa.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - ivabradine hydrochloride - angina pectoris; heart failure - it-terapija tal-qalb - kura sintomatika ta kronika stabbli, anġina pectorisivabradine huwa indikat għat-trattament tas-sintomi ta ' angina pectoris kronika stabbli fil-mard tal-arterji koronarji adulti b'ritmu sinusali normali u rata tal-qalb ≥ 70 bpm. ivabradine huwa indikat:fl-adulti li ma jistgħux jittolleraw jew bil-kontra-indikazzjoni għall-użu tal-beta-blockersor flimkien ma ' beta blockers f'pazjenti mhux ikkontrollati adegwatament bil-aħjar beta-blocker-doża. it-trattament tal-qalb kroniku failureivabradine huwa indikat f'insuffiċjenza kronika tal-qalb nyha ii-iv tal-klassi b'disfunzjoni sistolika, fil-pazjenti fl-sinus ritmiku u li d-rata tal-qalb huwa ≥ 75 bpm, f'kombinazzjoni ma ' terapija standard, inklużi l-beta-blockers jew meta beta-blockers huwa kontra-indikati jew mhux ittollerati.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

recordati rare diseases - betaine anidru - homocystinurja - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - adjunctive treatment of homocystinuria, involving deficiencies or defects in:cystathionine beta-synthase (cbs);5,10-methylene-tetrahydrofolate reductase (mthfr);cobalamin cofactor metabolism (cbl). cystadane should be used as supplement to other therapies such as vitamin b6 (pyridoxine), vitamin b12 (cobalamin), folate and a specific diet.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - majloma multipla - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. f'kombinazzjoni ma 'bortezomib, thalidomide u dexamethasone għat-trattament ta' pazjenti adulti li jkunu għadhom kif ġew dijanjostikati mjeloma multipla li huma eliġibbli għall-awtologi-trapjant ta'ċelloli staminali. f'kombinazzjoni ma ' lenalidomide u dexamethasone, jew bortezomib u dexamethasone, għat-trattament ta'pazjenti adulti b'mjeloma multipla li rċievew mill-inqas terapija waħda qabel. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. bħala monoterapija għall-kura ta ' pazjenti adulti b'all rikadut u refrattarji mjeloma multipla, li qabel it-terapija inkluż inibitur tal-proteasome u immunomodulatorji-aġent u li jkunu wrew-progressjoni tal-marda fl-aħħar terapija. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

zentiva k.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; stomach neoplasms; breast neoplasms - aġenti antineoplastiċi - tas-sider cancerdocetaxel winthrop flimkien ma 'doxorubicin u cyclophosphamide huwa indikat għall-kura awżiljarja ta' pazjenti bi:operabbli node-kanċer tas-sider posittiv;operabbli node negattivi għall-kanċer tas-sider. għall-pazjenti b'operabbli node negattivi għall-kanċer tas-sider, adjuvant it-trattament għandu jkun ristrett għal pazjenti eliġibbli li jirċievu l-kimoterapija skond internazzjonalment stabbiliti l-kriterji għall-primarja terapija tal-kanċer tas-sider bikri. docetaxel winthrop flimkien ma 'doxorubicin huwa indikat għat-trattament ta' pazjenti b'avvanzat lokalment jew metastatiku tas-sider tal-kanċer li ma kinux ħadu qabel terapija ċitotossika għal din il-kundizzjoni. docetaxel winthrop meta jingħata waħdu huwa indikat għat-trattament ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' terapija ċitotossika. kemjoterapija preċedenti kellha tinkludi anthracycline jew aġent alkilanti. docetaxel winthrop flimkien ma 'trastuzumab huwa indikat għat-trattament ta' pazjenti b'kanċer tas-sider metastatiku li t-tumuri tagħhom jesprimu bil-qawwa her2, u li preċedentement ma kienux ħadu kimoterapija għall-mard metastatiku. docetaxel winthrop flimkien ma 'capecitabine huwa indikat għat-trattament ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. mhux żgħar tal-pulmun taċ-ċelluli cancerdocetaxel winthrop huwa indikat għat-trattament ta ' pazjenti b'lokalment avvanzat jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelloli tal-kanċer wara l-falliment tal-kimoterapija qabel. docetaxel winthrop flimkien ma 'cisplatin huwa indikat għat-trattament ta' pazjenti li ma jistax jitneħħa, avvanzat lokalment jew dak metastatiku li mhux żgħar tal-pulmun taċ-ċelluli tal-kanċer, f'pazjenti li ma kinux ħadu qabel terapija ċitotossika għal din il-kundizzjoni. - prostata cancerdocetaxel winthrop flimkien ma 'prednisone jew prednisolone huwa indikat għat-trattament ta' pazjenti b'refrattorju għall-ormoni kanċer metastatiku tal-prostata. - istonku adenocarcinomadocetaxel winthrop flimkien ma 'cisplatin u 5-fluorouracil huwa indikat għat-trattament ta' pazjenti b'adenokarċinoma gastrika metastatika, inkluż l-adenokarċinoma ta ' l-istonku junction, li ma ħadu l-kimoterapija qabel, għal mard metastatiku. - ras u l-għonq cancerdocetaxel winthrop flimkien ma 'cisplatin u 5-fluorouracil huwa indikat għat-trattament induttiv ta' pazjenti b'lokalment avvanzat tal-karċinoma b'ċelloli squamous tar-ras u l-għonq.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmoloġiċi - it-tnaqqis tal-pressjoni intraocular (iop) fil-pazjenti adulti ma miftuħ-angolu glaucoma jew ipertensjoni okulari li huma responsivi biżżejjed biex beta-blockers topika jew analogi prostaglandin.